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Hydroxyurea (HU) is the most important advance in the treatment of sickle cell anaemia (SCA) 
for preventing complications and improving quality of life for patients. However, some aspects of 
treatment with HU remain unclear, including their effect on and potential toxicity to other blood cells 
such as neutrophils. This study used the measurement of Lactate Dehydrogenase (LDH) and Methyl 
ThiazolTetrazolium (MTT) and the comet assay to investigate the cytotoxicity and damage index (DI) of 
the DNA in the neutrophils of patients with SCA using HU.In the LDH and MTT assays, a cytoprotective 
effect was observed in the group of patients treated, as well as an absence of toxicity. When compared to 
patients without the treatment, the SS group (n=20, 13 women and 07 men, aged 18-69 years), and the 
group of healthy individuals (AA) used as a control group (n=52, 28 women and 24 men, aged 19-60 
years), The SSHU group (n=21, 11 women and 10 men, aged 19-63 years) showed a significant reduction 
(p<0.001) in LDH activity and an increase in the percentage of viable cells by the MTT (p<0.001). 
However, the SSHU group presented significantly higher DI values (49.57±6.0 U/A) when compared 
to the AA group (7.43 ± 0,94U/A) and the SS group (22.73 ±5.58 U/A) (p<0.0001), especially when 
treated for longer periods (>20 months), demonstrating that despite the cytoprotective effects in terms 
of cell viability, the use of HU can induce DNA damage in neutrophils.
Uniterms: Hydroxyurea/cytotoxicity. Sickle cell anaemia/treatment. Neutrophils/DNA damage. 
Deoxyribonucleic acid/damage.
A hidroxiuréia (HU) constitui o avanço mais importante no tratamento da anemia falciforme (AF) por 
prevenir complicações e aumentar a qualidade de vida dos pacientes. Entretanto, alguns aspectos do 
tratamento com HU permanecem obscuros, incluindo a sua ação e potencial toxicidade em outras células 
sanguíneas, tais como neutrófilos. Este estudo utilizou a mensuração da lactato desidrogenase (LDH) e 
do metil tiazoltetrazólio (MTT) e o ensaio do cometa para investigar a citotoxicidade e índice de dano 
(ID) ao DNA em neutrófilos de pacientes com AF em uso do medicamento. Nos ensaios de LDH e MTT, 
observou-se além de ausência de toxicidade, uma ação citoprotetora no grupo de pacientes tratados, 
Grupo SSHU (n=21, 11 mulheres e 10 homens, com idades entre 19-63 anos), quando comparados aos 
pacientes sem tratamento, Grupo SS (n=20, 13 mulheres e 07 homens, 18-69 anos), e grupo de indivíduos 
saudáveis (AA) usado como controle (n=52, 28 mulheres e 24 homens, 19-60 anos), com redução 
significativa (p<0,001) na atividade de LDH e aumento no percentual de células viáveis pelo MTT 
(p<0,001). Entretanto, o grupo SSHU apresentou valores de ID significativamente elevados (49,57±6,0 
U/A), quando comparados ao grupo AA (7,43 ± 0,94U/A) e grupo SS (22,73 ±5,58 U/A) (p<0,0001), 
especialmente quando tratados por períodos mais longos (>20 meses), demonstrando que apesar dos 
efeitos citoprotetores quanto à viabilidade celular, o uso da HU pode induzir lesão ao DNA de neutrófilos.
Unitermos: Hidroxiuréia/citotoxicidade. Anemia falciforme/tratamento. Neutrófilos/lesão ao DNA. 
Ácido desoxirribonucleico/lesão.
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INTRODUCTION
Sickle cell anaemia (SCA) is a hereditary disease 
caused by the substitution of glutamic acid with valine in 
the sixth codon of the β-globin leading to the formation 
of haemoglobin S (HbS). The sickle red blood cell is rigid 
and inflexible, favoring the occurrence of vaso-occlusive 
and haemolytic events and starting a chain reaction that 
culminates with the generation of reactive oxygen species 
(ROS), reduced bioavailability of nitric oxide (NO) and 
the chronic inflammatory process, with direct involvement 
of neutrophils in the early stages and propagation of these 
mechanisms (Okpala, 2004; Conran et al., 2007; Rees, 
Gibson, 2011; Chirico, Pialoux, 2012).
The leukocytes play an important role in the 
pathophysiology of SCA. The vaso-occlusive process 
and endothelial injury result in a chronic inflammatory 
response characterized by high levels of proinflammatory 
cytokines, which are capable of making the activated 
endothelium. The endothelial activation results in increased 
expression of adhesion molecules on neutrophils, such as 
E-selectin, P-selectin and ICAM-1 (Intercellular Adhesion 
Molecule-1), inducing the chemotaxis of neutrophils and 
its interaction with adhesion molecules on sickle red blood 
cells, other leukocytes and platelets, leading to pancellular 
activation resulting in the release of most proinflammatory 
cytokines. Thus, there is a vicious circle between production 
of inflammatory mediators and cellular adhesion to the 
endothelium, leading to a state of chronic inflammation, 
fundamental to the process of vaso-occlusion (Okpala, 
2006; Canalli et al., 2008; Conran, Franco-Penteado, Costa, 
2009; Segel, Halterman, Lichtman, 2011).
The high count of neutrophils, often seen in patients 
with SCA, even in the absence of infection, has been 
associated with the occurrence of painful crises, acute 
chest syndrome (ACS), cerebrovascular accident (CVA) 
and early death; however, the mechanisms responsible 
for this are not completely understood (Platt et al., 1994; 
Castro et al., 1994; Ohene-Frempong et al., 1998). Some 
factors that may cause the interruption of apoptosis, such 
as proinflammatory cytokines, cell adhesion, hypoxia, 
and transmigration of bacterial lipopolysaccharide (LPS) 
may be related to the increased number of neutrophils and 
the survival time of these cells, suggesting an important 
relevance to the pathogenesis of SCA, since changes in 
the processes of apoptosis may affect cellular function 
and increase the damage potential (Ohene-Frempong et 
al., 1998; Moulding et al., 1998; Cross et al., 2005; Cross 
et al., 2006; Conran et al., 2007).
Hydroxyurea (HU) is the only drug approved by the 
U.S. Food and Drug Administration (1999) and European 
Medicines Agency (2008) for the treatment of SCA. HU 
inhibits the enzyme ribonucleotide reductase (RNR), 
causes cell-cycle arrest, and allows globin genes to be 
more actively expressed. By killing cycling cells, HU 
changes the kinetics of erythroid proliferation, forcing 
more F cells to be produced from primitive progenitors 
and directly stimulating HbF production (Franco et al., 
2006).Furthermore, HU therapy increases haemoglobin 
concentration, reduces the expression of adhesion 
molecules on erythrocytes, platelets and neutrophils, 
decreases the production of granulocytes and contributes 
to the improvement of clinical events, reducing the number 
of hospital admissions, the frequency of painful episodes, 
the need for transfusion and the occurrence of CVA and 
ACS (Platt et al., 1984; Steinberg et al., 2003; Zago, Pinto, 
2007; Cartron, Elion, 2008; Orah, Platt, 2008; Conran, 
Franco-Penteado, Costa, 2009; Lou et al., 2009).
Despite these benefits the HU therapy may have 
clastogenic, mutagenic and teratogenic effects (Murphy, 
Chaube, 1964; Oppenheim, Fishbein, 1965; Aliverti, 
Bonanomi, Giavini, 1980; Ware, Aygun, 2009). In the 
literature, the HU ability to cause cancer is controversial 
and the long-term efficacy and safety of HU in treating 
patients with SCA remains inconclusive (Steinberg 
et al., 2010). Some studies have shown that HU is 
genotoxic while other studies suggest that HU has low 
mutagenicity in vivo (Hanft et al., 2000; Friedrisch et al., 
2008). Furthermore, some reports relate that HU acts as 
a competitive inhibitor of catalase-mediated hydrogen 
peroxide decomposition and this effect could be related 
to in vivo toxicity (Juul et al., 2010).
The long term safety of using HU remains an 
important issue, especially regarding genotoxicity and cell 
damage, and impact on the function of different organs 
(spleen kidneys, brain, lings) (Cançado et al., 2009).
Thus, some aspects regarding the treatment with 
HU and the safety of its long term use are still not fully 
elucidated, especially its effect on other blood cells other 
than erythrocytes. Therefore, it is necessary to evaluate the 
effect of HU regarding the genotoxicity and cytotoxicity in 
neutrophils isolated from patients with sickle cell anaemia 
at baseline, seeking evidence about the effect of HU on 
these cells and its influence on the modulation of the 
chronic inflammatory process in these patients.
MATERIAL AND METHODS
Criteria for inclusion
Subjects and samples
This is a cross-sectional study of 41 adult patients 
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(24 women and 17 men, aged 18-69 years) with clinical 
and laboratory diagnosis (confirmed by haemoglobin 
electrophoresis and molecular biology) of sickle cell 
anaemia (homozygotic SS form), representing 50% of the 
patients attending the outpatient unit of the haematology 
service of a reference hospital in Fortaleza, CE, Brazil 
(Table I presents the characteristics and clinical details of all 
individuals participating in the study). The study included 
SCA patients in a stable condition, according to the criteria 
of Ballas: absence of painful episodes and/or intercurrent 
illnesses, such as infections and inflammations in the four 
weeks preceding the study; no hospital admissions in the 
2-3 days preceding the study and no blood transfusions in 
the four months preceding the study (Ballas, 2012).
In Brazil, the Ministry of Health degree nº 872 of 6th 
November 2002 approved the use of HU for patients with 
sickle cell disease. The drug is recommended for patients 
with a laboratory diagnosis of sickle cell disease (HbSS, 
S/β Thalassemia, HbSC, Hb SD), including children with 
three or more episodes of vaso-occlusive crises requiring 
hospital medical care; a recurring acute chest crises; 
one or more strokes; recurrent priapism and severe and 
persistent anaemia in the past 12 months,Hb concentration 
consistently less than 7 g/dL, concentration of fetal 
Hb<8% after 2 years of age, WBC count 20x109/L in the 
absence of infection. Patients with hypersensitivity to HU 
will be excluded from this protocol, as well as patients 
with presence of at least one of the following items related 
to bone marrow dysfunction: neutrophils <2.5x109/L, 
platelets <95x109/L,Hb concentration <4.5 g/dL 
or reticulocyte count <95 x 109/L, pregnant women and 
HIV-infected patients (Brazil, 2002; Cançado et al., 2009).
The selected patients were divided into two groups 
according to the use of HU: SS (without HU treatment) 
(n=20, 13 women and 07 men, aged 18-69 years) 
and SSHU (receiving oral HU dose between 15 and 
25mg/kg/day) (n=21, 11 women and 10 men, aged 
19-63 years). A control group (AA) was made up of 
52 healthy blood donors (28 women and 24 men, aged 
19-60 years) from a blood center in Fortaleza, CE, 
Brazil. Exclusion criteria for all groups were: presence 
of infectious diseases (HIV-1 and 2, HBsAg, HCV and 
HTLV-1 & 2), pregnancy, presence of renal failure or liver 
disease, smoking, alcohol consumption, use of chelated 
iron, anti-inflammatory drugs, antioxidant vitamins, or 
any immunosuppressant. The survey was approved by 
the Ethics Committee of the Federal University of Ceará 
(COMEP/Protocol number 101/12), and all subjects signed 
an informed consent form. Samples (10 mL) of peripheral 
blood were collected with EDTA for molecular biology. 
Samples (10 mL) of heparinized peripheral blood were 
collected for isolation of polymorphonuclear leukocytes, 
predominantly neutrophils.
Molecular biological analysis
Molecular diagnosis of patients was based on a 
Polymerase Chain Reaction for mediated Restriction 
Fragment Length Polymorphism (PCR-RFLP), by 
digestion with DdeI restriction enzyme, according to the 
methods of Saiki et al. (1985).
Isolation of polymorphonuclear leukocytes
The isolation of polymorphonuclear leukocytes 
was carried from whole blood by differential gradient 
TABLE I -Characteristics and clinical details of the control group and patients with sickle cell anemia participating in the study
AA (n= 52) SS (n= 20) SSHU (n= 21)
Male/Female 24/28 07/13 10/11
Age (years) 34.6 (19; 60) 30 (18; 69) 32.17 (19; 63)
Red blood cell count (x1012 /L) 4.6 (4.2; 5.7) 2.66 (1.77; 4.0) 2.61 (1.73; 3.82)
Haemoglobin(g/dL) 13.5(12.2; 15.2) 8.4 (5.8; 11.5) 9.5 (7.4; 11.7)
Haematocrit(%) 41 (37; 49) 24.33 (16.9; 32.9) 27.05 (21.8; 33.4)
MCV (fL) 87 (79; 92.1) 91.1 (74.4; 107.6) 103.4 (79.7; 130.4)
MCH (pg) 28.9(25.9; 31.6) 31.5 (28.7; 37.7) 36.2 (29.5; 45.5)
White blood cell (x109/L) 5.7 (4.1; 8.4) 13.7 (5.5; 22.1) 9.4 (4.0; 19.7)
Neutrophil(%) 47 (39; 51) 59 (39; 85) 47.2 (31; 72)
Reticulocytes(x103/ µL) UD 272.5 (110.9; 597.8) 235.4 (110.5; 433.3)
Platelets(x 106/µL) 220 (148; 312) 371 (154; 798) 388.2 (385; 880.4)
HbF(%) UD 5.66 (1.0; 13.8) 15.77 (6.0; 38.7)
AA: Control group (healthy individuals); SS: patients with sickle cell anaemia not treated with HU; SSHU: patients with sickle 
cell anaemia treated with HU; MCV: Mean Corpuscular Volume; MCH: Mean Corpuscular Haemoglobin; UD: Undetermined.
The figures presented (except M/F) represent the average (minimum and maximum).
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using a gelatin solution, following the methodology 
proposed by Henson (1971) and modified by Lucisano and 
Mantovani (1984) in which the cells were suspended in 
buffered Hank’s balanced solution, containing calcium and 
magnesium. The preparations contained predominantly 
neutrophils (85.0 ± 2.8%).
Cell viability assay
Cell viability was determined by a Trypan Blue 
dye exclusion assay, in which the neutrophil suspension 
(2.5x106/mL) was mixed with an equal volume of Trypan 
Blue dye, 0.1%, and transferred to a Neubauer chamber. 
The Trypan Blue dye incorporated only non-viable cells 
due to membrane lesions (Lucisano, Mantovani, 1984). 
The proportion of viable cells was estimated by counting 
200 cells in an optical microscope.
Cytotoxicity assays
The cytotoxicity was analyzed by lactatedehydro-
genase (LDH) release, which assesses cell death by 
necrosis, and by the MethylThiazolTetrazolium (MTT) 
assay, measuring cellular metabolic activity through the 
pathway succinate-tetrazolium redutase, enzyme active 
only in cells with intact respiratory metabolism, which 
reduces the tetrazolium salt (yellow coloration) to a salt 
purple colour (formazan) (Renzi, Valtolina, Forster, 1993).
After isolation, a suspension of cells (2.5 × 106/mL) 
was incubated with buffered Hank’s balanced solution (test 
group) or 0.2% Triton X-100 (known to cause cell lysis and 
used as a positive control), for 30 min at 37°C. The activity 
of LDH was determined in the supernatant according to 
the manufacturer’s instructions (LDH liquiform of Labtest 
Diagnosis, MG, Brazil) in which the consumption of NADH 
was monitored by conversion of pyruvate to lactate at 
340 nm. A solution of MTT at a concentration of 10 mg/mL 
was added to a cell suspension of neutrophils (5.0x106/mL) 
for the colorimetric determination of the formazan crystals 
at 540 nm, according to the protocol described by Mosmann 
(1983).
Comet assay
The standard alkaline protocol for comet assay was 
used, as reported by Singh et al. (1988). The assay was 
performed in accordance with general guidelines for in 
vivo use of the comet assay (Tice et al., 2000; Hartmann 
et al., 2003). Briefly, the neutrophil suspension (2.5x106 
cells/mL) was mixed with low-melting-point agarose 
and spread onto glass slides pre-coated with agarose, and 
cover slips were gently placed over their content. Once 
the samples solidified, the cover slips were removed 
and the slides were soaked in freshly made, chilled lysis 
solution (2.5M NaCl, 100 mM EDTA, 10 mM Tris, pH 
10.2, to which 1% Triton X-100 and 10% DMSO had 
been added) for 1-2 days under refrigeration. Excess liquid 
was blotted away from each slide’s back and edges; the 
slides were then transferred to an electrophoresis tank, 
and an alkaline solution (300 mM NaOH, 1 mM EDTA, 
pH>13) was added. The slides were exposed to the alkaline 
solution for 20 min to allow for DNA unwinding and for 
the expression of alkali-labile sites as single strand breaks. 
DNA was then electrophoresed for 20 min (25 V; 300 mA; 
0.9 V/cm). Slides were removed from the electrophoresis 
tank, cleaned, washed three times (5 min each time) with 
neutralization buffer (0.4M Tris, pH 7.5), washed three 
times with distilled water, and allowed to air dry. All steps 
of the assay were conducted under dim light.
Slides were then fixed and silver-stained according 
to the methods of Nadin, Vargas-Roig and Ciocca (2001).
For evaluation of DNA damage, 100 cells per subject were 
analyzed at 200x magnification under a light microscope. 
Cells were assessed visually and received scores from 0 
(no migration) to 4 (maximum migration) according to 
tail intensity (size and shape). Therefore, the total scores 
(damage index or DI) for 100 cells ranged from 0 (all 
cells with no migration) to 400 (all cells with maximum 
migration). Slides from patients and controls were 
processed, coded, mixed, and evaluated together.
Statistical analyses
The Statistical Package for the Social Sciences 
(SPSS) 10.0 for Windows was used for all data analyses, 
and graphs were made with the GraphPad Prism 4.0 
for Windows. The level of significance was 0.05 for all 
tests, and the data is presented as mean ± S.E. of the 
mean (SEM). The Kolmogorov-Smirnov test was used to 
check for normal distribution of the data. The Analysis of 
variance (ANOVA) followed by the Tukey post-test was 
used to determine statistical differences between groups 
AA, SS and SSHU. The parametric T-test was used to test 
the influence of the mean dose of HU and HU Length of 
treatment on LDH release, MTT reduction and DI values. 
The mean dose of HU and the treatment length were 
separated into two categories according to their medians.
RESULTS
Influence of treatment with HU on cell viability 
evaluated by exclusion assay with Trypan Blue dye 
in neutrophils from patients with sickle cell anaemia
Table II shows that the number of viable cells of 
the SS group (93.7±0.34%) was significantly lower than 
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in the AA group (95.8±0.29%) (p<0.05). The number of 
viable cells in the SSHU group (95.0±0.42%) was similar 
to the SS and control groups, i.e., there was no significant 
difference.
Influence of treatment with HU on LDH release 
and MTT reduction in neutrophils from patients 
with sickle cell anaemia
Table III shows that the SS group (10.25 ± 1.21U/L) 
showed a greater LDH release compared to the AA group 
(6.71±0.68 U/L) and the SSHU group (5.59±0.37U/L) 
(p=0.0003). The LDH release did not differ between the 
SSHU and the AA groups (p>0.05).In the experimental 
model MTT reduction, the SS group (35.14±2.32%) 
showed a lower number of viable cells when compared to 
the AA group (56.8±3.2%) and the SSHU group (50.59 ± 
3.64%) (p<0.0001). There was no significant difference 
between the number of viable cells in the SSHU and the 
AA groups (p> 0.05). The mean dose of HU and the Length 
of HU treatment did not affect the LDH release and MTT 
reduction (Table IV).
Influence of treatment with HU in the DI values in 
neutrophils from patients with sickle cell anaemia
Figure 1 shows an association between DI values 
and treatment with HU. DI values for the SSHU group 
were greater (49.57 ± 6.0U/A) when compared to the AA 
group (7.43± 0.94 U/A) and the SS group (22.73 ± 5.58 
U/A) (p<0.0001). The SS group showed DI values higher 
than in the AA group, but the difference was not significant 
(p> 0.05). The mean dose of HU and the Length of HU 
treatment did not affect the DI values (Table IV).
DISCUSSION
The clinical and laboratory efficacy of HU in the 
TABLE II - Influence of treatment with HU on cell viability 
evaluated by exclusion assay with Trypan Blue dye in 
neutrophils from patients with sickle cell anaemia
Numberofcells (%)
Viable Non-viable p
AA (n=52) 95.8±0.29 4.2±0.33 p>0.05
SS (n=20) 93.7 ±0.34a 6.2 ±0.35 p<0.05
SSHU (n=21) 95.0 ±0.42 5.0 ±0.42 p>0.05
AA: Control group (healthy individuals), SS: patients with sickle 
cell anaemia not treated with HU; SSHU: patients with sickle 
cell anaemia treated with HU. Results were expressed as mean 
± SEM. ANOVA followed by Tukeypost test. a p<0.05 versus 
AA group.
TABLE III - Influence of treatment with HU in the parameters of cytotoxicity in neutrophils from patients with sickle cell anaemia
Parameters AA (n=52) SS (n=20) SSHU (n=21) p
LDH release (U/L) 6.71 ± 0.68 10.25 ± 1.21 a 5.59 ± 0.37 b 0.0003
MTT reduction (% de viable cells) 56.80 ± 3.20 35.14 ± 2.32 a 50.59 ± 3.64 b <0.0001
AA: Control group (healthy individuals), SS: patients with sickle cell anaemia not treated with HU; SSHU: patients with sickle 
cell anaemia treated with HU. Results were expressed asmean ± SEM. ANOVA followed by Tukeypost test. a p<0.05 versus AA 
group, b p<0.05 versus SS group
TABLE IV - LDH release, MTT reduction and DNA damage according to length of HU treatment and mean HU dose (SSHU group) 
(n=21)
LDH release 
(U/L)
p MTT reduction 
(% de viable cells)
p DI values 
(U/A)
p
Mean dose of HU (n)
<20.0 mg/kg HU (15) 6.18 ± 0.68 0.289 51.60 ± 8.43 0.825 51.70 ± 5.70 0.098
≥20.0 mg/kg HU (6) 5.32 ± 0.44 49.90 ± 3.18 28.67 ± 7.39
Length of HU treatment (n)
≤20months (8) 5.88 ± 0.64 0.925 44.81 ± 3.44 0.220 25.92 ± 7.10 0.002*
>20months (13) 5.81 ± 0.44 51.12 ± 3.56 59.0 ± 6.39
Results were expressed as mean ± SEM. Student t-Test. * p<0.05.
A. M. Pedrosa, M. C. Barbosa, T. N. Santos, L. K. A. M. Leal, A. A. Lopes, D. B. D. Elias, G. L. Sasahara, B. C. Cavalcanti, R. P. Gonçalves406
treatment of SCA has been convincingly demonstrated, 
with a decrease in morbidity and mortality with HU use, 
coupled with the modest short-term toxicity profile and 
ease of once daily oral administration, HU is an ideal 
treatment option (Ware, 2010).These consistent results 
leave little question as to the clinical benefits of HU 
therapy for adults with SCA. However, the long-term 
efficacy and safety of HU use for patients with SCA 
remains one of the most critical unanswered questions 
(Brawley et al., 2008), and not much is known about 
the effects of this medicament on neutrophils and on 
the functionality of these cells, since the majority of the 
studies found in the literature are related to red blood cells.
The results of this study showed that patients with 
SCA not treated with HU showed significantly lower cell 
viability, both the cellular viability assay by Trypan Blue 
dye as well as the MTT assay, and increased LDH release 
compared to the control group (AA). Similar results 
are found in studies with erythrocytes of SCA patients, 
revealing an increase in plasma levels of LDH of patients 
when compared to healthy individuals (Kato et al., 2006; 
Cançado et al., 2009), and this increase in enzymes is 
positively associated with an increased risk that patients will 
suffer from priapism, pulmonary hypertension, cutaneous 
ulcers in the lower limbs, resistance to NO or even early 
death (Kato et al., 2006; Steinberg, 2008; Rees, Gibson, 
2011). There was no significant difference of these variables 
between the patients treated with HU and the control 
group (AA). These results suggest that neutrophils from 
patients with SCA not treated with HU do have damage of 
cellular integrity and respiratory metabolism, and that HU 
did not have any cytotoxic effect on patients’ neutrophils 
when investigated using these testing models. However, a 
cytoprotective action was revealed when compared to the 
AA group and the SS patients. It is also possible that the 
oxidative stress and generalized inflammation of severe 
untreated SCA produces a mild cytotoxic effect, and HU 
therapy may help to improve this process.
To evaluate the DNA damage index by comet assay, 
it was observed that the SCA patients not treated with 
HU had DI values higher than the AA group, but with 
no significant difference. No correlation was observed 
between the DI values with the HbF parameters and the 
total white blood cell count in the groups studied. Some 
studies show conflicting results, suggesting that mutagenic 
or carcinogenic effects are induced by the disease itself 
rather than by HU therapy (Schultz, Ware, 2003; Segal 
et al., 2008). For example, in a retrospective survey by 
the International Association of Sickle Cell Nurses and 
Physician Assistants, 52 cases of cancer were identified in 
a cohort of more than 16,000 patients with SCA; almost 
all occurred in the pre-HU stage; only three patients had 
previous HU exposure; among children with SCA, 21 
reported cancers included leukemia (n=7), Wilms tumor 
(n=5), lymphoma (n=3), and six other solid tumors; 
only one patient with acute lymphoblastic leukemia had 
previous HU exposure (Schultz, Ware, 2003).
There are conflicting reports regarding the DNA-
damaging potential of HU in exposed humans. Some studies 
have shown that HU is genotoxic (Flanagan et al., 2010; 
Juul et al., 2010; Santos et al., 2011) while other studies 
suggest that HU has low mutagenicity in vivo (Stricker et 
al., 1986; Dawkins et al., 1997; Montalembert et al., 1999; 
Hanft et al., 2000; Montalembert, Davies, 2001; Moschovi 
et al., 2001). In this study, patients with SCA treated with 
HU had significantly elevated DI values when compared 
with the patients with SCA who were not treated with HU. 
Furthermore, the DI values were significantly higher in 
patients treated for longer periods (>20 months).Similar 
results were found in two previous studies that evaluated 
the DNA Damage Index in total peripheral white blood 
cell counts of SCA patients treated with HU (Friedrisch et 
al., 2008; Rocha et al., 2012). Taken together, these studies 
provide evidence for measurable genotoxicity from HU 
exposure in patients with SCA, but little evidence to support 
cumulative mutagenicity or carcinogenic potential.
CONCLUSION
Although HU presents numerous positive responses, 
more studies on the issue of safety are essential, including 
FIGURE 1 – Influence of treatment with HU on the DI values in 
neutrophils from patients with sickle cell anaemia. AA: Control 
group (healthy individuals) (n=52); SS: patients with sickle cell 
anaemia not treated with HU (n=20); SSHU: patients with sickle 
cell anaemia treated with HU (n=21). Results were expressed 
as mean ± SEM. ANOVA followed by turkey posttest. ap0.05 
versus AA group. b0.05 versus SS group
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the optimal dosage, the duration of use and the age 
of the patient, among other factors. Currently SCA 
is characterized as a chronic inflammatory disease 
where neutrophils initiate leukocyte adhesion to blood 
vessel walls, contributing thus to the development of 
inflammatory and vaso-occlusive processes and to the 
severity of the disease. Despite evidence of the essential 
involvement of neutrophils in the clinical modulation 
and the pathophysiological aspects of the disease, the 
mechanism by which HU modulates this effect is not fully 
elucidated. This study demonstrates that treatment with 
HU does not exert a cytotoxic effect on the neutrophils of 
patients with SCA, and HU may even be able to promote a 
protective effect on these cells, however there is the risk of 
DNA damage associated with exposure for longer periods 
of time. The monitoring of patients with SCA is important, 
since the data on the cytotoxic and genotoxic risks of HU 
remain inconclusive. More research is needed to clarify 
the risks of HU therapy inpatients with SCA.
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